日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting Aurora kinase B regulates cholesterol metabolism and enhances chemoimmunotherapy in cholangiocarcinoma

靶向 Aurora 激酶 B 可调节胆固醇代谢并增强胆管癌的化疗免疫疗法疗效

Liu, Furong; Chen, Wei; Zhang, Ze; Zeng, Weifeng; Hu, Haofan; Ning, Shangwu; Liao, Zhibin; Liu, Yachong; Zhang, Hongwei; Fu, Qinggang; Zhang, Bixiang; Chen, Xiaoping; Zhang, Wanguang; Zhang, Zhanguo

Targeting SPAK suppresses progression and averts an immune exhaustive microenvironment in hepatocellular carcinoma

靶向SPAK可抑制肝细胞癌的进展并避免免疫耗竭的微环境。

Pan, Yonglong; Zeng, Chenglong; He, Yi; Chang, Ruizhi; Wu, Jingjing; Yuan, Chaoyi; Li, Haisen; Su, Chen; Han, Mengzhen; Li, Pengcheng; Li, Xinxin; Zhang, Hongwei; Liu, Furong; Liang, Huifang; Li, Zifu; Wu, Mi; Xia, Limin; Liu, Jianfeng; Chen, Xiaoping; Zhang, Wanguang; Zhang, Bixiang; Ding, Ze-Yang

Oxygenation: Nanotechnological Strategies for Conquering Tumor Hypoxia in Photodynamic Therapy

氧合作用:纳米技术策略在光动力疗法中克服肿瘤乏氧

Liang, Jingru; Lai, Xiujun; Mei, Yujia; Liu, Xingyun; Wen, Shunbo; Zhou, Yusheng; Liu, Furong

Hemoglobin glycation index and mortality risk in severe community-acquired pneumonia: a retrospective study

血红蛋白糖化指数与重症社区获得性肺炎死亡风险:一项回顾性研究

Jiang, Jiaru; Xie, Pingqian; Tan, Lele; Jiang, Hanlin; Tian, Yufeng; Xiao, Jiangbo; Liu, Furong; Xie, Rongjun; He, Chengjian; Yao, Hongyi

Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study

TAS-102联合苏鲁替尼治疗三线及后续转移性胰腺癌的疗效和安全性:一项前瞻性、单中心、生物标志物探索性II期研究

Lu, Yunxin; Lin, Qingguang; Mo, Yongxin; Liu, Furong; Zhang, Mengwei; Huang, Runjie; Wang, Yun; Wang, Yinnan; Wang, Zhiqiang; Luo, Huiyan; Guo, Guifang; Chen, Jianwen; Liu, Yu; He, Mingming; Wang, Fenghua; Wang, Feng; Zhang, Dongsheng

iMeta Conference 2025: Creating high-impact international journals

2025年iMeta会议:创建高影响力国际期刊

Zhu, Zhihao; Zhang, Lin; Yao, Xiaofang; Zeng, Meiyin; Wang, Yao; Luo, Hao; Zhou, Yuanping; Zhang, Tianyuan; Xun, Jiani; Bai, Defeng; Yang, Haifei; Xu, Shanshan; Zhou, Yang; Gao, Yunyun; Xu, Jinbo; Han, Wei; Shen, ZiAng; Zhang, Bangzhou; Ma, Tengfei; Wan, Xiu-Lin; Ma, Chuang; Hui, Fengjiao; Bai, Hao; Bai, Lijing; Bai, Qing; Bao, Qiangguo; Cao, Guodong; Cao, Peng; Cao, Qiqi; Chen, Hu; Chen, Jiawen; Chen, Jiaxu; Chen, Lihua; Chen, Tingting; Chen, Yi; Cui, Haipeng; Dai, Shaoxing; Dai, Xi-Jian; Dai, Xiaofeng; Dang, Yanqi; Deng, Lei; Deng, Yun; Ding, Xia; Dong, Binhua; Dong, Ling; Dou, Shujie; Du, Hongzhi; Fang, Zhencheng; Feng, Xiaoxiao; Fu, Min; Gao, Yuan; Gong, Wenping; Guo, Xiang; Han, Wenjie; Hao, Zikai; He, Zheng-Guo; Hu, Haibo; Hu, Haiming; Hu, Xuefei; Huang, Liang; Huang, Xianya; Huang, Xueting; Hui, Haochen; Jia, Dingjiacheng; Jiang, Aimin; Jiang, Di; Jiang, Kun; Jiang, Dewei; Jin, Ying; Lai, Kunyang; Li, Chun; Li, Feng; Li, Fuyong; Li, Jing; Li, Juan; Li, Junling; Li, Kui; Li, Ling; Li, Moli; Li, Peiwu; Li, Peng; Li, Runze; Li, Shengnan; Li, Shujin; Li, Wanting; Li, Wenting; Li, Xiaojing; Li, Xinrui; Li, Xuemeng; Liang, Qiqi; Liao, Xiaoping; Liu, Boyang; Liu, Canzhao; Liu, Chang; Liu, Duanrui; Liu, Furong; Liu, Jianjun; Liu, Jinyao; Liu, Siqi; Liu, Tianyang; Liu, Wenjuan; Liu, Yan; Liu, Yang; Liu, Yi; Liu, Yuan; Liu, Yunhuan; Liu, Zhipeng; Liu, Zhiyong; Lu, Xin; Luo, Xiao; Ma, Guanju; Meng, Jialin; Meng, Yuanfa; Miao, Runyu; Miao, Linxuan; Ni, Yawen; Niu, Dongze; Niu, Tingting; Pan, Hongzhao; Qin, Guoqiang; Qiu, Tiantian; Qiu, Yueping; Qu, Hui; Qu, Linghang; Ren, Na; Sun, Qiang; Shang, Run; She, Peize; Shen, Xihui; Shi, Bohan; Shu, You; Song, Jiawei; Song, Weibin; Su, Qi; Sun, Qingzhu; Sun, YuPing; Sun, Zijin; Tang, Bufu; Tang, Deqin; Tang, Hua; Tao, Yongfu; Teng, Teng; Tu, Yanye; Wang, Cheng; Wang, Hui; Wang, Yunhao; Wang, Chunli; Wang, Dingjie; Wang, Gang; Wang, Jin; Wang, Kaiyi; Wang, Mingbang; Wang, Shan; Wang, Shixiang; Wang, Xiaojie; Wang, Xing-Chang; Wang, Yunzhe; Wang, Jiale; Wang, Zheng; Wang, Weijie; Wei, Yongjun; Xu, Wei; Wu, Fan; Wu, Junling; Wu, Shijuan; Xiao, Jian; Xiao, Weihua; Xiao, Yang; Xiong, Xi; Xiong, Xue; Xu, Feng; Xu, Junyu; Xu, Wen; Xu, Jun; Xu, Yao; Yan, Jun; Yao, Lutian; Yang, Jia; Yang, Lulu; Yang, Xingzhen; Yin, Naiyi; You, Hua; You, Min; Yu, Ting; Yu, Yongyao; Yu, Renqiang; Yuan, Shuofeng; Yue, Chaoxiong; Zeng, Xiaoya; Zha, Andong; Zhai, Leilei; Zhang, Chi; Zhang, Dong; Zhang, Hengguo; Zhang, Heng; Zhang, Hongyu; Zhang, Jiahao; Zhang, Jinyang; Zhang, Lishan; Zhang, Qi; Zhang, Xiang; Zhang, Xiangyu; Zhang, Xuelei; Zhang, Yancong; Zhang, Yuan; Zhang, Zhenyu; Zhao, Jiwei; Zhao, Jingxuan; Zhao, Kai; Zhao, Mingjuan; Zhao, Yi; Zhao, Yunxiang; Zhong, Jixin; Zhong, Ling; Zhong, Xiangjian; Zhou, Dan; Zhou, Wei; Zhou, Wen; Zhou, Yiqian; Zhou, Zhemin; Zhu, Shiquan; Liu, Shuang-Jiang; Feng, Suyin; Jin, Shuangxia; Xiao, Chuanxing; Wang, Ziheng; Luo, Peng; Chen, Tong; Chen, Gang; Liu, Yong-Xin

Correspondence to editorial on "Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma"

致编辑的信函,主题为“靶向TM4SF1促进肿瘤衰老,增强CD8+ T细胞在肝细胞癌中的细胞毒性功能”

Zeng, Weifeng; Liu, Furong; Liu, Yachong; Zhang, Zhanguo

Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma.

靶向 TM4SF1 可促进肿瘤衰老,增强 CD8+ T 细胞在肝细胞癌中的细胞毒性功能

Zeng Weifeng, Liu Furong, Liu Yachong, Zhang Ze, Hu Haofan, Ning Shangwu, Zhang Hongwei, Chen Xiaoping, Liao Zhibin, Zhang Zhanguo

VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization

VRK2靶向治疗通过MYC去稳定化增强抗PD-1免疫疗法在肝细胞癌中的疗效

Su, Chen; Liao, Zhibin; Mo, Jie; Liu, Furong; Wang, Weijian; Zhang, Haoquan; Zhang, Hongwei; Liu, Yachong; Pan, Yonglong; Zhu, He; Chen, Xiaoping; Zhang, Zhanguo; Zhu, Peng; Zhang, Bixiang

Unveiling the crossroads of STING signaling pathway and metabolic reprogramming: the multifaceted role of the STING in the TME and new prospects in cancer therapies

揭示STING信号通路与代谢重编程的交汇点:STING在肿瘤微环境中的多重作用及其在癌症治疗中的新前景

Wang, Siwei; Qin, Lu; Liu, Furong; Zhang, Zhanguo